BCRX
BIOCRYST PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$8.68
−0.23%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$8.65
From 52W high−21.87%
Volume12.66M
Market cap$2.22B
P/E (TTM)—
P/S (TTM)2.4x
Div yield—
Key dataSep 18, 2026
Open
$8.65
From 52W high
−21.87%
Volume
12.66M
Market cap
$2.22B
ValuationView details →
P/E (Fwd)
16.7x
EV/EBITDA
−7.5x
P/E (TTM)
—
RSI (14)
41.2
MomentumView details →
1D Return
−0.23%
YTD Return
+10.65%
SummaryUpdated Jun 1, 2026
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a biotechnology company founded in 1986 and headquartered in Durham, North Carolina. The company went public in 1994 and has evolved from a drug discovery platform focused on structure-based drug design into a commercial-stage biopharmaceutical company. BioCryst specializes in developing oral, small-molecule medicines for rare diseases, with its flagship product ORLADEYO becoming a significant commercial success in treating hereditary angioedema. The company has transitioned from a research-focused entity burning substantial cash to approaching profitability, driven primarily by the strong commercial performance of its lead drug.
Similar companies
Latest newsMore news →
BioCryst announced that Japan approved ORLADEYO for pediatric hereditary angioedema patients aged 2 and older, expanding availability of the oral prophylactic therapy.26d agoBioCryst Pharmaceuticals began shipping ORLADEYO oral pellets to pediatric patients on August 3, 2026.46d agoBioCryst Pharmaceuticals completed enrollment in ALPHA-ORBIT, the ongoing pivotal study of navenibart.46d ago